Ulcerative Colitis - Page 6 
The MD Magazine Ulcerative Colitis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Sponsored

Brooks Cash from the University of South Alabama Health System: Determining Safety and Efficacy in New IBS Treatment
The development of new medications for any condition requires attention to detail in a number of areas, especially safety and efficacy. A recent drug developed for irritable bowel syndrome (IBS) looked to be effective in both areas prior to its approval.
The new Rome IV criteria classify the functional bowel disorders into five distinct categories, including irritable bowel syndrome (IBS), functional constipation, functional diarrhea, functional abdominal bloating/distention, and unspecified functional bowel disorder. A new category for opioid-induced constipation, which is distinct from the functional bowel disorders, has been added.
Rome IV updates include more specific definitions and diagnostic criteria for functional gastroduodenal disorders such as functional dyspepsia, belching disorders, and nausea and vomiting disorders.
The Rome Foundation announced the release of updated and revised Rome IV diagnostic criteria for more than 20 different gastrointestinal disorders at DDW 2016.
Endoscopic retrograde cholangiopancreatography is a common procedure in adult patients but a recent study looked at whether the procedure was safe for younger patients and whether it provided the same level of efficacy.
Golimumab injections continue to prove effective and safe for patients with moderate-to-severe ulcerative colitis, according to a recent study.
Treatment isn’t enough to keep ulcerative colitis relapses at bay; dietary factors play in an important role in flares as well. New research identifies foods that patients should stay away from.
Patients who stop infliximab 12 months after they started are at higher risk of relapse if those patients earlier had ulcerative colitis.
Could a special type of intestinal cell be at the root of inflammatory bowel disease? Researchers from Rutgers University Newark (RU N) believed so, and wanted to determine how to alter the cells’ behavior to eliminate the disease.

Most Popular

@MDMagazine

$vacMongoViewPlus$ $vAR$